Evidence map›Paper›PMID 35972337›Full record

ArticleThe oncologist2022

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.

Melinda L Hsu, Joseph C Murray, Kevin J Psoter, Jiajia Zhang, Durrant Barasa, Julie R Brahmer, David S Ettinger, Patrick M Forde, Christine L Hann, Vincent K Lam and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Melinda L HsuSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-0200-1579
Joseph C MurraySidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Kevin J PsoterDepartment of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
Jiajia ZhangSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Durrant BarasaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Julie R BrahmerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
David S EttingerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Patrick M FordeSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Christine L HannSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Vincent K LamSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Benjamin LevySidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Kristen A MarroneSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Tricia Patel
Valerie Peterson
Sarah Sagorsky
Michelle TurnerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Valsamo AnagnostouSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Jarushka NaidooSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Josephine L FelicianoSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Bloomberg (United States) · USSidney Kimmel Comprehensive Cancer Center · USJohns Hopkins University · US

Funding

Large-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3M
NCI NIH HHS R01 CA121113
6 · The paper itself

Abstract

introductionAnti-PD-(L)1 immune checkpoint inhibitors (ICI) improve survival in patients with advanced non-small cell lung cancer (aNSCLC). The clinical features, survival, and burden of toxicities of patients with aNSCLC alive >1 year from ICI initiation are poorly understood. MATERIALS AND

methodsWe defined ICI survivors as patients alive >1 year after ICI start and retrospectively reviewed demographics, treatment, and immune-related adverse events (irAEs). Long-term irAEs were defined as ongoing irAEs lasting >1 year; burden of toxicity measures were based on percentage of days a patient experienced toxicity. Using linear and logistic regression, we evaluated association between demographics and disease characteristics with burden of toxicity.

resultsWe identified 114 ICI survivors from 317 patients with aNSCLC. Half (52%) experienced an irAE of any grade, and 23.7% developed long-term irAEs. More ICI survivors with irAES in the first year had never smoked (P = .018) or received ICIs as frontline therapy (P = .015). The burden of toxicity in the first year significantly correlated with the burden of toxicity afterward (ρ = 0.72; P < .001). No patients with progressive disease had a high burden of toxicity, and they experienced 30.6% fewer days with toxicity than those with stable disease. Increased duration of therapy was associated with higher odds of experiencing toxicity. Half of ICI survivors with irAEs were still receiving treatment for unresolved irAEs at time of death or last follow-up.

conclusionSignificant proportions of ICI survivors have unresolved long-term toxicities. These data support a growing need to understand long-term toxicity to optimize management of those treated with ICIs.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunologic FactorsImmunotherapyRetrospective StudiesSurvivorsAntineoplastic Agents, ImmunologicalImmunologic Factorsimmune checkpoint inhibitorsimmune-related adverse eventsnon-small cell lung cancersurvivorshiptoxicities

Identifiers

PMID35972337
PMCPMC9632301
OpenAlexW4292063882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.